Evotec and Boehringer Ingelheim Extend and Broaden Research
Collaboration
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ - Strategic research collaboration continues for another 4 years at avalue of EUR 15 million plus milestones and royalties -Hamburg, Germany - 9 November 2009: Evotec AG (Frankfurt StockExchange: EVT; TecDAX, NASDAQ: EVTC) today announced that it hasextended the research collaboration with Boehringer Ingelheim for afurther 4 years. The collaboration was initiated in August 2004 andhas been extended on two previous occasions. At the same time, basedon the success to date in the areas of CNS, inflammation,cardiometabolic and respiratory diseases the scope of thecollaboration has been expanded to also include oncology targets.Over the term of the extension Evotec will receive research fundingof around EUR 15 million plus success milestones and royalties.Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented:"We are extremely pleased and proud that Boehringer Ingelheimcontinues to see the value that we bring to their research, bycommitting to one of the largest and most innovative integratedresearch projects in the industry. This extension speaks volumes forthe excellent scientific results achieved."Dr Wolfgang Rettig, Corporate Senior Vice President Research ofBoehringer Ingelheim, commented: "Evotec has continually demonstratedexceptional scientific expertise in support of our research. We arevery pleased to be able to continue our collaboration with Evotec andexpand it into new areas of research and have no doubt that they willcontinue to assist us in achieving our drug discovery goals."About the CollaborationIn 2004, Evotec and Boehringer Ingelheim entered into a multiyeardrug discovery collaboration to jointly identify and developpreclinical development candidates for the treatment of variousdiseases. Under the terms of the agreement, Boehringer Ingelheim hasfull ownership and global responsibility for clinical development,manufacturing and commercialisation of the compounds identified. Inreturn, Evotec receives ongoing research payments and preclinicalmilestones. Furthermore, the contract provides substantial long-termupside for Evotec through potential payments for successful milestoneachievements during clinical development and royalties when new drugsreach the market.Contact: Dr Werner Lanthaler, Chief Executive Officer,Evotec AG, Tel.: +49.(0)40.56081-242, werner.lanthaler(at)evotec.comForward-Looking StatementsInformation set forth in this press release contains forward-lookingstatements, which involve a number of risks and uncertainties. Suchforward-looking statements include, but are not limited to,statements about our expectations and assumptions concerningregulatory, clinical and business strategies, the progress of ourclinical development programs and timing of the results of ourclinical trials, strategic collaborations and management's plans,objectives and strategies. These statements are neither promises norguarantees, but are subject to a variety of risks and uncertainties,many of which are beyond our control, and which could cause actualresults to differ materially from those contemplated in theseforward-looking statements. In particular, the risks anduncertainties include, among other things: risks that the Company maybe unable to reduce its cash burn through recent restructuring andcost containment measures and may not recognize the results of suchmeasures within the expected timeframe; risks that product candidatesmay fail in the clinic or may not be successfully marketed ormanufactured; the risk that we will not achieve the anticipatedbenefits of our collaborations, partnerships and acquisitions in thetimeframes expected, or at all; risks relating to our ability toadvance the development of product candidates currently in thepipeline or in clinical trials; our inability to further identify,develop and achieve commercial success for new products andtechnologies; the risk that competing products may be moresuccessful; our inability to interest potential partners in ourtechnologies and products; our inability to achieve commercialsuccess for our products and technologies; our inability to protectour intellectual property and the cost of enforcing or defending ourintellectual property rights; our failure to comply with regulationsrelating to our products and product candidates, including FDArequirements; the risk that the FDA may interpret the results of ourstudies differently than we have; the risk that clinical trials maynot result in marketable products; the risk that we may be unable tosuccessfully secure regulatory approval of and market our drugcandidates; and risks of new, changing and competitive technologiesand regulations in the U.S. and internationally.The list of risks above is not exhaustive. Our most recent AnnualReport on Form 20-F, filed with the Securities and ExchangeCommission, and other documents filed with, or furnished to theSecurities and Exchange Commission, contain additional factors thatcould impact our businesses and financial performance. We expresslydisclaim any obligation or undertaking to release publicly anyupdates or revisions to any such statements to reflect any change inour expectations or any change in events, conditions or circumstanceson which any such statement is based.http://hugin.info/131215/R/1353562/327876.pdf --- End of Message ---Evotec AGSchnackenburgallee 114 Hamburg GermanyWKN: 566480; ISIN: DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All Share;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 09.11.2009 - 10:20 Uhr
Sprache: Deutsch
News-ID 8107
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 212 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Evotec and Boehringer Ingelheim Extend and Broaden Research
Collaboration"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
